U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356713) titled 'A Study to Find a Suitable Dose of Exl-111 for Further Research' on Dec. 11, 2025.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 in healthy participants.
The trials consists of 2 parts, as follows:
Part A (SAD): Up to 5 dose cohorts, each with 8 participants, randomized into 2 arms: Exl-111 and placebo.
Part B (MAD): Up to 3 dose cohorts, each with 10 participants, randomized into 3 arms: Exl-111, placebo, and an active comparator (omalizumab).
Study Start Date: Jan. 12
Study Type: INTERVENTIONAL
Condition:
Allergic Disease
Intervention:
D...